Solventum announced today it intends to separate its Health Information Systems division — the business that processes 660 million clinical documents monthly and is embedded in more than 75% of U.S. hospitals. The spinout timeline is 12–18 months. The RCM implications are significant.
Solventum (NYSE: SOLV) disclosed that its Board of Directors has approved a plan to evaluate and pursue the separation of its Health Information Systems (HIS) business. The company is assessing multiple structures — independent spinout, combination with a scaled strategic buyer, or another transaction format — with Morgan Stanley and Goldman Sachs advising.
The target timeline is completion within 12–18 months. No structure has been finalized, and Solventum acknowledged a transaction may not occur.
Annual revenue generated by the HIS division (12 months ended Dec 31, 2025)
of U.S. hospitals using HIS solutions — medical coding, RCM software, clinician productivity tools
Clinical documents processed monthly by the HIS platform
Estimated addressable market, growing 5–6% annually per Solventum
The rationale: Solventum wants to be a pure-play MedTech company (MedSurg and Dental Solutions). HIS is a healthcare software business — strategically different enough that combined ownership was compressing the value of both.
This isn't a minor product line. The HIS business is what most RCM teams know as the 3M Health Information Systems legacy — 40+ years of medical coding infrastructure, including the proprietary rules engine that underpins clinical documentation and coding accuracy for a majority of the U.S. acute care market.
The portfolio includes:
It operates across 30+ countries and runs on long-term contracts with deep workflow integrations. This isn't a subscription tool a health system can swap out on a quarterly budget cycle. These contracts are measured in years and renewals.
The practical answer: if your organization runs 3M CAC, uses 3M 360 Encompass, or has any HIS-branded coding or CDI tooling, you are going to be navigating a vendor ownership transition within the next 18–24 months.
That creates real operational questions:
A private equity buyer acquiring HIS would almost certainly mean a profitability focus over a 5–7 year hold period. That typically translates to contract price escalation, slower product investment, and pressure on support staffing. Hospitals that have been running aging 3M installations without evaluating alternatives would be in the worst negotiating position. Now is a reasonable time to understand your options.
Solventum specifically called out autonomous coding as a growth driver for a separated HIS entity. That's a pointed signal.
The CAC market is at an inflection: traditional computer-assisted coding — AI that suggests codes for human review — is being challenged by fully autonomous systems that submit without human review. 3M/HIS has been moving in that direction, but the pace has been constrained by operating inside a diversified MedTech company with competing capital priorities.
An independent HIS with clean capital allocation could accelerate autonomous coding significantly. That's good for the hospital market in the long run — faster path to reduced coder headcount dependency and better coding accuracy. It's also a direct competitive threat to the emerging autonomous coding vendors (Fathom, Avanza, MD.ai and others) that have been gaining ground in the absence of aggressive 3M investment.
The business embedded in most U.S. hospital revenue cycles is going independent. The 12–18 month transition window is long enough that nothing needs to change today — but short enough that now is the right time to pull your HIS contract terms, understand your renewal dates, and have a contingency conversation with your CDI and coding leadership about what vendor diversification would look like. Waiting until the deal closes is waiting too long.
Solventum is running a formal strategic process. The 12–18 month target is aggressive for a transaction of this complexity — $1.4B in revenue, global operations, deep technology integration dependencies. Expect:
The company will update on the separation alongside its regular quarterly earnings cadence. No additional disclosures were made in connection with today's announcement.
Payor policy shifts, vendor moves, denial trends — before they hit your A/R. Free for revenue cycle teams.